A Pilot Study to Obtain Preliminary Information Regarding the Efficacy and Safety of the Combination of Immune Globulin and Ganciclovir as Compared to Ganciclovir Alone in the Treatment of Sight-Threatening CMV Retinitis in Patients With AIDS

• Status: Completed
• Trial end date: 1969-12-31

Summary

To evaluate whether immune globulin and ganciclovir (DHPG) results in faster initial response as compared to DHPG alone. To evaluate whether immune globulin and DHPG gives longer duration of remission than DHPG alone (i.e. 16 weeks). To evaluate the toxicities of the combination of DHPG and immune globulin as compared to those of DHPG alone. To evaluate if there is a difference between the two groups in regard to survival, immune functions, and CMV viremia and viruria.

• Phase: N/A

Details

• Lead Sponsor: American National Red Cross
• Treatments: Antibodies; gamma-Globulins; Ganciclovir; Ganciclovir triphosphate; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin